HLA antigens and seronegative rheumatoid arthritis

T BARDIN, L LEGRAND, B NAPEAU, A MARCELLI-BARGE, N DEBEYRE, G M LATHROP, J C POIRIER, M SCHMID, A RYCKEWAERT, AND A DRYLL

From the 1Clinique Rhumatologique de l'Hôpital Lariboisière, 6 rue Guy Patin, 75010 Paris; 2Unité INSERM U 93, Hôpital Saint-Louis, Paris; 3Laboratoire d'Anthropologie Biologique, Université Paris 7, Paris

SUMMARY HLA antigens and clinical features in a series of 46 Caucasian patients (40 females, 6 males) with definite repeatedly seronegative rheumatoid arthritis (RA) of more than two years' duration (mean 11.6 years) were compared with those in 77 seropositive RA patients and 110 controls of the same ethnic and geographic origin. Seronegative RA appeared to be less often erosive than seropositive RA, and seronegative patients had fewer extra-articular features. The frequency of the HLA antigen DR1 was raised in seronegative patients as compared with controls (p=0.006, relative risk=3) and with seropositive patients (p<0.05). HLA-DR4 was slightly increased in seronegative patients compared with controls (p<0.05) but was clearly less so than in seropositive patients (p<0.005). Early onset of disease was very significantly associated with HLA-DR1 in seronegative patients (p=0.007), whereas HLA-DR4 was present more frequently in seropositive patients with onset prior to age 35 (p<0.05). No correlation between HLA antigens and intolerances to drugs was found in seronegative patients, whereas in seropositive patients side effects to gold salts were associated with DR3. These results suggest that seropositive and seronegative RA have distinct HLA-DR associations, especially in disease of early onset, in addition to well established clinical differences.

Key words: HLA system, rheumatoid factor, rheumatoid arthritis, gold salts.

The association of seropositive rheumatoid arthritis (RA) with the HLA system has been well established in several ethnic groups. Seropositive RA has been repeatedly shown to be associated with the HLA antigen DR4 in Caucasians,1-11 blacks,11,12 Latin Americans,1 and Japanese.13 In Asian Indians, according to one report,7 and in Jews14 the disease has been correlated with DR1. Only in one population, the Yakima Indians, is seropositive RA not correlated with HLA antigens.15 In contrast, studies of HLA antigens in seronegative RA have given disparate results. Some investigators have reported a high frequency of HLA-DR4 in seronegative RA,2,4,8,13 whereas another group showed a high frequency of DR1.9 Other studies have not shown any HLA antigen association with seronegative RA,1,3,6 Moreover some researchers have found an association of seronegative RA with the antigen DR4 in black patients12 but no HLA associations with the same disease in Caucasians.6 These discrepancies prompted us to study the HLA antigen distribution in a series of 46 carefully selected patients with seronegative RA and to compare the antigen frequencies obtained with those, already reported elsewhere,7 observed in 77 seropositive RA patients and 110 controls of similar ethnic and geographic origin.16 In addition clinical features of the disease were recorded and compared in the two series of patients.

Patients and methods

Forty-six Caucasian patients from the Paris area were selected according to the following criteria: (1) Seronegative RA was the working diagnosis of the rheumatologist in charge of the patient. (2) RA was definite or classical according to ARA criteria.17 Other seronegative arthritides were carefully ex-
cluded: in particular all patients had normal sacroiliac x-rays, and none had a familial history of psoriasis or ankylosing spondylitis. (3) Articular involvement was roughly symmetrical and predominantly distal. (4) Disease duration exceeded two years. (5) Search for rheumatoid factor had been repeatedly and consistently negative by two methods, namely latex F II and Waaler-Rose tests. Seronegativity was defined as latex determination <1/80 and Waaler-Rose <1/40.

All the patients were re-examined for the purpose of the study. Their clinical notes were also reviewed to assess disease duration and severity, type and tolerance of treatments, and to look for an extra-articular involvement. Schirmer and Rose Bengal tests were recorded in 27 patients’ notes, and positivity of these two tests was the criterion used for diagnosis of Sjögren’s syndrome. X-rays of the hands and wrists were taken at the time of the study and blood was drawn to perform latex and Waaler-Rose tests, a test for antinuclear antibodies (ANA) by indirect immunofluorescence using rat hepatocytes as a substrate, and HLA typing.

Patients were tested for 49 alleles of four HLA loci. HLA A, B, and C groups were determined by the microcytotoxicity method using peripheral blood.\textsuperscript{18} The DR specificities were determined by the standard technique described by Legrand and Dausset.\textsuperscript{19}

Unless otherwise stated, the $\chi^2$ test was used for statistical analysis of the results.

Results

Clinical data in seropositive and seronegative patients are summarised in Table 1. Seronegative patients appeared to have an erosive disease less often than seropositive patients, despite similar treatment and disease duration ($p<0.01$). Extra-articular features of the disease were more frequent in seropositive than in seronegative patients, especially Raynaud’s phenomenon, Sjögren’s syndrome and rheumatoid nodules. The number of patients with at least one extra-articular feature was significantly ($p<0.01$) higher in seropositive than in seronegative patients. Tolerance to treatments was similar in the two groups.

**HLA ANTIGENS**

No significant difference was found between the frequencies of HLA A, B, and C antigens among seropositive or seronegative patients and controls. In particular, the antigen B27 was found in 4% of seronegative RA patients and in respectively 8.7% and 10% of seropositive RA patients and controls.

Table 1: Clinical features in the two series of RA patients

<table>
<thead>
<tr>
<th>Feature</th>
<th>Seronegative patients (n=46)</th>
<th>Seropositive patients (n=77)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/F ratio</td>
<td>6/40</td>
<td>16/61</td>
</tr>
<tr>
<td>Age of onset (yrs) mean</td>
<td>49</td>
<td>41-4</td>
</tr>
<tr>
<td>Patients with erosive arthritis\textsuperscript{*}</td>
<td>(18-72)</td>
<td>(17-80)</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Rheumatoid nodules</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Episceritis</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Cutaneous vasculitis</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Neuritis multiplex</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Seritis</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Amyloidosis</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>5/27</td>
<td>25/64</td>
</tr>
</tbody>
</table>

(*p<0.01.*

Frequencies of B7-CREG did not differ significantly in the three groups.

The HLA-DR distributions in the 46 seronegative RA patients as well as in 77 seropositive RA patients and in 110 controls are shown in Table 2. These distributions differed in several respects. The DR1 frequency was clearly increased in seronegative RA patients as compared with controls ($p=0.006$), whereas this frequency appeared similar in seropositive patients and in controls. The DR4 frequency was slightly elevated in seronegative patients ($\chi^2=4 p<0.05$) as compared with controls but was significantly less than in seropositive patients ($p<0.005$). The relative risk for seronegative RA was three for the antigen DR1 and 2.4 for the antigen DR4.

Table 2: Distribution of DR antigens in seronegative and seropositive RA patients and controls

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Seronegative RA (46 patients)</th>
<th>Seropositive RA (77 patients)</th>
<th>Controls (110)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR1</td>
<td>15 (32.6%)</td>
<td>13 (16.9%)</td>
<td>15 (13.6%)</td>
</tr>
<tr>
<td>DR2</td>
<td>11 (23.9%)</td>
<td>24 (31.2%)</td>
<td>34 (30.9%)</td>
</tr>
<tr>
<td>DR3</td>
<td>13 (28.2%)</td>
<td>23 (29.9%)</td>
<td>24 (21.8%)</td>
</tr>
<tr>
<td>DR4</td>
<td>14 (30.4%)</td>
<td>51 (66.2%)</td>
<td>17 (16.3%)</td>
</tr>
<tr>
<td>DR5</td>
<td>8 (17.4%)</td>
<td>12 (15.6%)</td>
<td>38 (34.5%)</td>
</tr>
<tr>
<td>DR6</td>
<td>9 (19.6%)</td>
<td>3 (3.9%)</td>
<td>15 (13.6%)</td>
</tr>
<tr>
<td>DR7</td>
<td>11 (23.9%)</td>
<td>9 (11.7%)</td>
<td>34 (30.9%)</td>
</tr>
<tr>
<td>DR8</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>3 (2.7%)</td>
</tr>
<tr>
<td>Blank</td>
<td>11 (23.9%)</td>
<td>19 (24.7%)</td>
<td>40 (36.3%)</td>
</tr>
</tbody>
</table>
The correlation of clinical features with HLA antigens differed in the two series of patients. In seropositive RA patients early onset of disease was clearly associated with the HLA-DR1 antigen \((p=0.007, \text{ Wilcoxon rank test})\). In these patients the mean age of onset was 38-47 for DR1 positive patients and 53-87 for DR1 negative patients. In contrast, in the seropositive RA patients DR4 was found most frequently when onset was prior to age 35 \((p<0.05)\), as already reported. A correlation between the antigen DR3 and intolerance to gold salts (aurothiopropanol sulphonate) was found in seropositive patients and has been reported elsewhere. In seronegative patients 15 developed intolerance to gold salts, including four with proteinuria, 10 with cutaneous intolerance, and one with stomatitis. Only four of these patients and one of the four patients with renal intolerance were positive for DR3 antigen versus five of 19 patients who had a high tolerance for the drug. Thus adverse reactions to gold salts do not seem to be correlated with the DR3 antigen in the seronegative patients. Similarly, none of the five seronegative patients who developed adverse reactions to D-penicillamine, including two cases of proteinuria, were DR3 positive, whereas three out of four seropositive patients with D-penicillamine induced proteinuria were DR3 positive. We have also reported on the decreased frequency of DR4 antigen in seropositive RA patients with Sjögren’s syndrome (SS) as compared with seropositive RA patients without SS. We were unable to test for such correlation in seronegative patients, as only five had Sjögren’s syndrome. Finally, no correlations were found between HLA antigens and disease severity, extra-articular features, or ANA status in the two series of patients.

Discussion

This study has allowed us to show several clinical and immunogenetical differences between seronegative and seropositive RA. From a clinical viewpoint the articular involvement was found to be less severe and the extra-articular features of the disease less frequent in seronegative RA patients. These findings are in agreement with those in previous studies which suggested that the articular prognosis was worse in seropositive than in seronegative RA and that extra-articular involvement, including rheumatoid nodules, vasculitis, and Sjögren’s syndrome correlated with seropositivity. In contrast, immunogenetic studies of seronegative RA have given conflicting results. Several groups reported a high HLA-DR4 frequency in seronegative as well as in seropositive RA patients, whereas others claimed that DR4 elevation was restricted to seropositive RA. These discrepancies are possibly due in part to differences in patient selection, as investigators have used different criteria for the diagnosis of seronegative RA. In our study particular attention was paid to selecting patients with a clinical profile suggesting RA and who were constantly seronegative by two methods, with a disease duration exceeding two years. In all cases the articular involvement was roughly symmetrical, with distal predominance, and other seronegative arthritides were carefully excluded. The population of patients we studied with seronegative rheumatoid arthritis clearly differed from seropositive patients and from controls. The frequency of HLA-DR4 was slightly elevated in seronegative patients in comparison with controls, but this increase is at the limit of statistical significance. In contrast the frequency of DR4 was very significantly elevated in seropositive patients as compared with controls \((p<10^{-9})\) and with seropositive patients \((p<0.005)\). On the other hand, the frequency of DR1 antigen was clearly elevated in seronegative patients as compared with controls. Interestingly we have shown that DR1 is associated with a slightly increased risk for seropositive RA when the data are corrected for the high DR4 frequency. Nevertheless, DR1 is significantly more frequent in seronegative patients as compared with seropositive patients \((p<0.05)\).

DR1 has been previously reported to be elevated in seropositive RA in Jewish populations and in Asian Indians, but to the best of our knowledge no mention has been made of its frequency in seronegative RA patients of these ethnic groups. In Caucasians the frequency of DR1 has been found to be elevated in seronegative RA in one study undertaken by Swiss investigators. Our results also suggest that DR1 is associated with seronegative RA in Caucasians. The correlation we found between DR1 and an early onset of seronegative RA supports the hypothesis of a susceptibility factor associated with this antigen.

Finally, we were unable to demonstrate any association between HLA antigens and intolerances to drugs in our series of seronegative RA patients. Several groups, including ours, have reported an increased risk for intolerance to gold salts or D-penicillamine treatments in seropositive RA patients carrying the DR3 antigen, but we do not know of other such studies in seronegative RA patients. Our results suggest that the association of DR3 with
adverse effects to gold salts and D-penicillamine treatments may be restricted to seropositive RA.

References


HLA antigens and seronegative rheumatoid arthritis.

T Bardin, L Legrand, B Naveau, A Marcelli-Barge, N Debeyre, G M Lathrop, J C Poirier, M Schmid, A Ryckewaert and A Dryll

*Ann Rheum Dis* 1985 44: 50-53
doi: 10.1136/ard.44.1.50

Updated information and services can be found at:

[http://ard.bmj.com/content/44/1/50](http://ard.bmj.com/content/44/1/50)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)